Control of macrophage metabolism and activation by mTOR and Akt signaling

Seminars in Immunology

Volumn 27, Issue 4, 2015, Pages 286-296

  Covarrubias, Anthony J ^a   Aksoylar, H Ibrahim ^a   Horng, Tiffany ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Akt; Immunometabolism; Macrophage activation; Macrophage metabolism; MTOR

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; GLUTAMINE; TARGET OF RAPAMYCIN KINASE;

CELL ACTIVITY; CELL METABOLISM; MACROPHAGE ACTIVATION; METABOLIC REGULATION; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ANIMAL; HUMAN; MACROPHAGE; METABOLISM;

ANIMALS; GLUTAMINE; HUMANS; MACROPHAGE ACTIVATION; MACROPHAGES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84951906010     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2015.08.001     Document Type: Review

References (66)

1. Dibble C.C., Manning B.D. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat. Cell Biol. 2013, 15(6):555-564.
2. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149(2):274-293.
3. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011, 11(11):723-737.
4. Davies L.C., Jenkins S.J., Allen J.E., Taylor P.R. Tissue-resident macrophages. Nat. Immunol. 2013, 14(10):986-995.
5. Byles V., et al. The TSC-mTOR pathway regulates macrophage polarization. Nat. Commun. 2013, 4:2834.
6. Van Dyken S.J., Locksley R.M. Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Ann. Rev. Immunol. 2013, 31:317-343.
7. Troutman T.D., et al. Role for B-cell adapter for PI3K (BCAP) as a signaling adapter linking Toll-like receptors (TLRs) to serine/threonine kinases PI3K/Akt. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(1):273-278.
8. Lee P.S., et al. mTORC1-S6K activation by endotoxin contributes to cytokine up-regulation and early lethality in animals. PloS One 2010, 5(12):e14399.
9. Lee D.F., et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 2007, 130(3):440-455.
10. Everts B., et al. TLR-driven early glycolytic reprogramming via the kinases TBK1-IKKvarepsilon supports the anabolic demands of dendritic cell activation. Nat. Immunol. 2014, 15(4):323-332.
11. Troutman T.D., Bazan J.F., Pasare C. Toll-like receptors, signaling adapters and regulation of the pro-inflammatory response by PI3K. Cell Cycle 2012, 11(19):3559-3567.
12. Fukao T., Koyasu S. PI3K and negative regulation of TLR signaling. Trends Immunol. 2003, 24(7):358-363.
13. Ruckerl D., et al. Induction of IL-4Ralpha-dependent microRNAs identifies PI3K/Akt signaling as essential for IL-4-driven murine macrophage proliferation in vivo. Blood 2012, 120(11):2307-2316.
14. Arranz A., et al. Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(24):9517-9522.
15. Fan W., et al. FoxO1 regulates Tlr4 inflammatory pathway signalling in macrophages. EMBO J. 2010, 29(24):4223-4236.
16. Howell J.J., Manning B.D. mTOR couples cellular nutrient sensing to organismal metabolic homeostasis. Trends Endocrinol. Metabol.: TEM 2011, 22(3):94-102.
17. Zhu L., et al. TSC1 controls macrophage polarization to prevent inflammatory disease. Nat. Commun. 2014, 5:4696.
18. Pan H., O'Brien T.F., Zhang P., Zhong X.P. The role of tuberous sclerosis complex 1 in regulating innate immunity. J. Immunol. 2012, 188(8):3658-3666.
19. Pan H., et al. Critical role of the tumor suppressor tuberous sclerosis complex 1 in dendritic cell activation of CD4 T cells by promoting MHC class II expression via IRF4 and CIITA. J. Immunol. 2013, 191(2):699-707.
20. Weichhart T., et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008, 29(4):565-577.
21. Yao S., et al. Interferon regulatory factor 4 sustains CD8(+) T cell expansion and effector differentiation. Immunity 2013, 39(5):833-845.
22. Man K., et al. The transcription factor IRF4 is essential for TCR affinity-mediated metabolic programming and clonal expansion of T cells. Nat. Immunol. 2013, 14(11):1155-1165.
23. Chawla A., Nguyen K.D., Goh Y.P. Macrophage-mediated inflammation in metabolic disease. Nat. Rev. Immunol. 2011, 11(11):738-749.
24. Jiang H., Westerterp M., Wang C., Zhu Y., Ai D. Macrophage mTORC1 disruption reduces inflammation and insulin resistance in obese mice. Diabetologia 2014, 57(11):2393-2404.
25. Ai D., et al. Disruption of mammalian target of rapamycin complex 1 in macrophages decreases chemokine gene expression and atherosclerosis. Circulat. Res. 2014, 114(10):1576-1584.
26. Festuccia W.T., Pouliot P., Bakan I., Sabatini D.M., Laplante M. Myeloid-specific Rictor deletion induces M1 macrophage polarization and potentiates in vivo pro-inflammatory response to lipopolysaccharide. PloS One 2014, 9(4):e95432.
27. Brown J., Wang H., Suttles J., Graves D.T., Martin M. Mammalian target of rapamycin complex 2 (mTORC2) negatively regulates Toll-like receptor 4-mediated inflammatory response via FoxO1. J. Biol. Chem. 2011, 286(52):44295-44305.
28. Odegaard J.I., et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007, 447(7148):1116-1120.
29. Kang K., et al. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metabol. 2008, 7(6):485-495.
30. Yang C.S., Yuk J.M., Jo E.K. The role of nitric oxide in mycobacterial infections. Immune Network 2009, 9(2):46-52.
31. Duque-Correa M.A., et al. Macrophage arginase-1 controls bacterial growth and pathology in hypoxic tuberculosis granulomas. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(38):E4024-E4032.
32. Colegio O.R., et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 2014, 513(7519):559-563.
33. Vats D., et al. Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. Cell Metabol. 2006, 4(1):13-24.
34. Tannahill G.M., et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature 2013, 496(7444):238-242.
35. Cramer T., et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 2003, 112(5):645-657.
36. Katada S., Imhof A., Sassone-Corsi P. Connecting threads: epigenetics and metabolism. Cell 2012, 148(1-2):24-28.
37. Choudhary C., Weinert B.T., Nishida Y., Verdin E., Mann M. The growing landscape of lysine acetylation links metabolism and cell signalling. Nat. Rev. Mol. Cell Biol. 2014, 15(8):536-550.
38. Pearce E.J., Everts B. Dendritic cell metabolism. Nat. Rev. Immunol. 2015, 15(1):18-29.
39. Galvan-Pena S., O'Neill L.A. Metabolic reprograming in macrophage polarization. Front. Immunol. 2014, 5:420.
40. Biswas S.K., Mantovani A. Orchestration of metabolism by macrophages. Cell Metabol. 2012, 15(4):432-437.
41. Robey R.B., Hay N. Is Akt the "Warburg kinase"?.-Akt-energy metabolism interactions and oncogenesis. Semin. Cancer Biol. 2009, 19(1):25-31.
42. Rodriguez-Prados J.C., et al. Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation. J. Immunol. 2010, 185(1):605-614.
43. Palsson-McDermott E.M., et al. Pyruvate kinase M2 regulates Hif-1alpha activity and IL-1beta induction and is a critical determinant of the warburg effect in LPS-activated macrophages. Cell Metabol. 2015, 21(1):65-80.
44. Haschemi A., et al. The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism. Cell Metabol. 2012, 15(6):813-826.
45. Infantino V., et al. The mitochondrial citrate carrier: a new player in inflammation. Biochem. J. 2011, 438(3):433-436.
46. Everts B., et al. Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells. Blood 2012, 120(7):1422-1431.
47. Jha A.K., et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity 2015, 42(3):419-430.
48. Michelucci A., et al. Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(19):7820-7825.
49. Huang S.C., et al. Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages. Nat. Immunol. 2014, 15(9):846-855.
50. Pello O.M., et al. Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Blood 2012, 119(2):411-421.
51. Im S.S., et al. Linking lipid metabolism to the innate immune response in macrophages through sterol regulatory element binding protein-1a. Cell Metabol. 2011, 13(5):540-549.
52. Maya-Monteiro C.M., et al. Leptin induces macrophage lipid body formation by a phosphatidylinositol 3-kinase- and mammalian target of rapamycin-dependent mechanism. J. Biol. Chem. 2008, 283(4):2203-2210.
53. Wang Y., et al. Tuberous sclerosis 1 (Tsc1)-dependent metabolic checkpoint controls development of dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(50):E4894-E4903.
54. Csibi A., et al. The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation. Curr. Biol.: CB 2014, 24(19):2274-2280.
55. Cheng S.C., et al. mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 2014, 345(6204):1250684.
56. Horng T. mTOR trains heightened macrophage responses. Trends Immunol. 2015, 36(1):1-2.
57. Price J.V., Vance R.E. The macrophage paradox. Immunity 2014, 41(5):685-693.
58. Tattoli I., et al. Amino acid starvation induced by invasive bacterial pathogens triggers an innate host defense program. Cell Host Microbe 2012, 11(6):563-575.
59. Xavier M.N., et al. PPARgamma-mediated increase in glucose availability sustains chronic Brucella abortus infection in alternatively activated macrophages. Cell Host Microbe 2013, 14(2):159-170.
60. Eisele N.A., et al. Salmonella require the fatty acid regulator PPARdelta for the establishment of a metabolic environment essential for long-term persistence. Cell Host Microbe 2013, 14(2):171-182.
61. Vander Heiden M.G. Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov. 2011, 10(9):671-684.
62. Gerriets V.A., et al. Metabolic programming and PDHK1 control CD4+T cell subsets and inflammation. J. Clin. Investigat. 2015, 125(1):194-207.
63. Glick G.D., et al. Anaplerotic metabolism of alloreactive T cells provides a metabolic approach to treat graft-versus-host disease. J. Pharmacol. Exp. Therapeut. 2014, 351(2):298-307.
64. Berod L., et al. De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat. Med. 2014, 20(11):1327-1333.
65. Singh A., Talekar M., Raikar A., Amiji M. Macrophage-targeted delivery systems for nucleic acid therapy of inflammatory diseases. J. Controlled Release: Off. J. Controlled Release Soc. 2014, 190:515-530.
66. Czech M.P., Aouadi M., Tesz G.J. RNAi-based therapeutic strategies for metabolic disease. Nat. Rev. Endocrinol. 2011, 7(8):473-484.